3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 2/3
2
Phase NA
1
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Ovarian Neoplasms
26
Uterine Cervical Neoplasms
16
Endometrial Neoplasms
14
Fallopian Tube Neoplasms
10
Carcinoma, Ovarian Epithelial
7
Colorectal Neoplasms
6
Peritoneal Neoplasms
5
Neoplasms
5
Uterine Cervical Dysplasia
4
Lung Neoplasms
4
Gestational Trophoblastic Disease
4
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Melanoma
3
Hematologic Neoplasms
3
Endometrial Hyperplasia
3
Urinary Bladder Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Progesterone Resistance
2
Ovarian Cysts
2
Obesity
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Interventions
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Cystadenocarcinoma, Serous
×
Gynecologic
×
Clear all
NCT04159155
2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3
Terminated
11 enrolled
NCT04055038
2019-08-13
EPITOC
Blokhin's Russian Cancer Research Center
Phase 2/3
Unknown
164 enrolled